title: Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency.
authors.affiliation: Evans Department of Clinical Research, Boston University Medical Center, Massachusetts 02118.
authors.forename: T
authors.initials: T
authors.lastname: Kiyokawa
authors.forename: D P
authors.initials: DP
authors.lastname: Williams
authors.forename: C E
authors.initials: CE
authors.lastname: Snider
authors.forename: C A
authors.initials: CA
authors.lastname: Waters
authors.forename: J C
authors.initials: JC
authors.lastname: Nichols
authors.forename: T B
authors.initials: TB
authors.lastname: Strom
authors.forename: J R
authors.initials: JR
authors.lastname: Murphy
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D004167:Diphtheria Toxin / Q000235:genetics / Q000494:pharmacology*; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000494:pharmacology*; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*
chemical_list: C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins